Brazzola and colleagues recently reported a case of fatal diffuse capillaritis after matched unrelated donor bone marrow transplant for dyskeratosis congenita (DC) despite using a minimal-intensity conditioning regimen of antithymocyte globulin (ATG), fludarabine and low-dose CY. We report a late death at 15 months post-BMT, due to gastrointestinal bleeding and obliterative fibro-alveolitis, following matched unrelated donor bone marrow transplant using alemtuzumab (campath), fludarabine and melphalan.
In 1985, the patient was diagnosed with inherited aplastic anaemia at the age of 6 years, but did not require treatment until the age of 11 years when he commenced oxymetholone with a successful response for 10 years. Family history revealed idiopathic pulmonary fibrosis (father and paternal grandmother) and his sister had non-severe aplastic anaemia. He had no evidence of Fanconi anaemia and did not display any clinical features typical of DC. . Unmanipulated bone marrow cells were given at a dose of 3.4 Â 10 8 nucleated cells per kg. CsA was used as post transplant immunosuppression. He achieved prompt and sustained engraftment with 100% donor chimerism, assessed using PCR of BM mononuclear cells for short tandem repeats. There was no evidence of acute or chronic GVHD.
From day þ 173 post transplant, he developed recurrent episodes of febrile neutropenia. High-resolution computer tomography (CT) of chest revealed a cavitating pulmonary lesion and subsequent histological diagnosis of obliterative fibro-alveolitis. No pathogen was identified on bronchoalveolar lavage. Twelve months post transplant, he presented with weight loss and anaemia and two episodes of severe upper GI bleeding. Oesophago-gastro-duodenoscopy (OGD) and colonoscopy did not reveal a site of active bleeding. Histology revealed mild mucosal inflammation of the stomach but no GVHD. CT scan of the abdomen revealed dilated portal vein with oedematous small bowel only. The patient developed ascites and ongoing melaena. Repeat CT scan of the abdomen showed prominent mesenteric lymphadenopathy with thickened ascending colon. Rituximab was given for suspected post transplant lymphoproliferative disease, although this was subsequently not confirmed.
Because of continued melaena, magnetic resonance imaging (MRI) venogram was performed and suggested portal hypertension secondary to cirrhotic liver, and the presence of oesophageal varices. A transjugular intrahepatic portosystemic shunt (TIPSS) procedure was performed with a transjugular biopsy of the liver along with variceal embolization. Histology from the liver biopsy showed nodular regenerative hyperplasia only. Pleural biopsy was performed on account of a large pleural effusion and recurrent fevers. He continued to deteriorate with acute renal failure, subsequently requiring haemodialysis. Further, OGD for continued melaena revealed extensive bleeding and erosive duodenitis. He continued to deteriorate and died 15 months post-BMT.
Post-mortem examination showed nodular regenerative hyperplasia in the liver causing portal hypertension and oesophageal varices. Pulmonary histology showed cryptogenic organizing pneumonia and obliterative bronchiolitis. Although initial findings were attributed to chronic GVHD, a diagnosis of DC was considered and proven in family members. Both the patient's sister and father were found to have a heterozygous telomerase RNA (TERC) mutation, consistent with autosomal-dominant DC. 1, 2 His mother was normal on testing. In addition to cryptogenic fibrosing alveolitis affecting the patient's father, subsequent family history emerged that the patient's paternal grandmother had anaemia and fibrosing alveolitis treated unsuccessfully with steroids and other immunosuppressive drugs. We therefore conclude that the pulmonary and hepatic findings at post mortem were most probably due to DC, although transplant-related issues may have contributed.
DC is an inherited disorder that usually presents with the clinical triad of abnormal skin pigmentation, nail dystrophy and mucosal leukoplakia. There are also noncutaneous manifestations such as gastrointestinal and pulmonary complications. 3 Allogeneic stem cell transplantation remains the only curative approach; however, outcomes have been poor due to early and late complications. 4 Success rates have been found to improve with fludarabine-based reduced-intensity conditioning regimes. Those conditioned with high-dose CY and BU in conjunction with radiotherapy, all died secondary to complications relating to liver, bowel or lung toxicity. 4 More recent studies have used reduced-intensity regimes with encouraging results. [5] [6] [7] However, since then it has been demonstrated that regardless of these regimes, fatality can still occur in some cases due to disease-specific complications. 8 In our case, we used a pretransplant conditioning of alemtuzumab, fludarabine and melphalan, with CSA but no MTX, following the reduced-intensity protocol of Kottaridis et al. 9 For aplastic anaemia patients, we now use a modification of this protocol, replacing melphalan with low dose CY, 300 mg m 2 Â 4. Death occurred due to gastrointestinal haemorrhage associated with obliterative fibro-alveolitis, probably related to the underlying diagnosis, although transplant-related issues may have contributed to the pulmonary problem. Prominent pulmonary pathology in two other members of this family (father and paternal grandmother) is noteworthy and suggests a high predilection to respiratory complications associated with DC in this family. It is important to note in our patient that pulmonary function pretransplant was normal with FEV1/FVC of 86%. In conclusion, this reduced-intensity regime of alemtuzumab, fludarabine and melphalan for stem cell transplantation does not eliminate the risk of later lethal complications in all DC patients. 
